Abstract:Background The rapid and accurate detection of thyroid-stimulating hormone (TSH) receptor antibodies has always been an urgent need for the clinical diagnosis and management of Graves’ disease (GD). We aimed to evaluate the use of an automated thyroid-stimulating immunoglobulin (TSI) bridge immunoassay in the diagnosis of GD and to analyze the relationship between TSI and the degree of hyperthyroidism. Methods A total of 227 new-onset GD patients, 29 Hashimoto thyroiditis, 43 non-autoimmune thyroid diseases and 37 euthyroid controls were consecutively recruited. All participants accepted the measurement of their serum thyroid function and thyroid-associated antibodies, including TSI being measured by an Immulite 2000 bridge immunoassay and TSH receptor autoantibodies (TRAb) being measured by a third-generation Roche electrochemiluminescence immunoassay. The quantitative consistency between the TSI and TRAb detection methods was analyzed by using Passing-Bablok regression and Bland–Altman plots. The diagnostic performance for GD was assessed by receiver operating characteristic (ROC) curve analysis. Results Among 227 GD patients (174 females and 53 males, with a mean age of 39 years), the quantitative TSI was positively correlated with TRAb ( r = 0.8099). According to the cut-off values proposed by the manufacturers (TSI: 0.55 IU/L, TRAb: 1.75 IU/L), the positive rates of TSI and TRAb in new-onset GD patients were 96.92% and 95.15%, respectively. Both TSI and TRAb levels positively correlated with FT 4 levels (TSI: r = 0.243, TRAb: r = 0.317; all P < 0.001) and FT 3 levels (TSI: r = 0.288, TRAb: r = 0.360; all P < 0.001) in new-onset GD patients. The ROC analysis showed that the optimal TSI cut-off value was 0.577 IU/L for GD diagnosis in this Chinese population, with a sensitivity of 96.92% and a specificity of 97.25%, respectively. The optimal TRAb cut-off value of was 1.38 IU/L, with a sensitivity of 96.92% and a specificity of 99.08%. There were no significant differences between the cut-off values obtained through the ROC analysis and those provided by the manufacturer for both TSI and TRAb when calculating their sensitivity and specificity in diagnosing GD. Among the 8 newly diagnosed GD cases with discordant qualitative antibody results, TSI was more likely than TRAb to match the clinical diagnosis of GD (6 TSI-positive vs. 2 TRAb-positive patients). Conclusion The automated TSI bridge immunoassay was positively correlated with thyroxine levels in new-onset GD patients and was more likely to be consistent with the clinical diagnosis of GD than with that of TRAb. The positive Immulite 2000 TSI cut-off value of 0.577 IU/L for GD diagnosis in the Chinese population were close to the value recommended by the manufacturer.

Progression of assay and clinical practice of thyroid stimulating hormone receptor antibody

Evaluation of the application of TSH receptor stimulating autoantibodies and the optimization of detection strategy in Graves’ disease

Retraction: Clinical Application of Thyrotropin Receptor Antibodies

Thyroid stimulating receptor autoantibodies

Evaluation of the diagnostic performance of thyroid‐stimulating immunoglobulin and thyrotropin receptor antibodies for Graves' disease

The clinical significance of TSAb in Graves' disease

Clinical Evaluation of an Automated TSI Bridge Immunoassay in the Diagnosis of Graves’ Disease and Its Relationship to the Degree of Hyperthyroidism

Study on thyrotropin receptor autoantibody in female patients with autoimmune thyroid disease determined by using recombinant human TSH receptor ectodomain

Evaluation of Analytic and Clinical Performance of Two Immunoassays for Detecting Thyroid‐stimulating Receptor Antibody in the Diagnosis of Graves’ Disease

Clinical Value of Thyroid-Stimulating Antibody Measurement Using CHO-hTSHR Cell Line

Clinical efficacy of thyroid-stimulating immunoglobulin detection for diagnosing Graves’ disease and predictors of responsiveness to methimazole

Diagnostic value of thyroid autoantibodies in Graves' disease

Consistency Between Thyrotropin Receptor Antibody (TRAb) and Thyroid-Stimulating Antibody (TSAb) Levels in Patients with Graves Disease.

Identification and functionalization of thyrotropin receptor antibodies with different antigenic epitopes

Stimulating thyrotropin receptor antibodies in early pregnancy

Study on the detection value of thyroid function and related antibody in Graves disease

US-based, Prospective, Blinded Study of Thyrotropin Receptor Antibody in Autoimmune Thyroid Disease

The Role of Preablative Stimulated Thyroglobulin in Guiding Risk Estimation and Therapeutic Decisions of Differentiated Thyroid Carcinoma

The Effect of Radioiodine Treatment on the Characteristics of TRAb in Graves’ Disease

Significance of detection of serum TRAb levels in diagnosis of patients with thyoid disease

Mechanism of Persistent Thyrotropin Suppression in Euthyroid Patients with Graves′ Disease after Treatment